ADAR1 Capital Management »

Q32 Bio shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Q32 Bio shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Q32 Bio

Tip: Access up to 7 years of quarterly data

All positions including Q32 Bio held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Q32 Bio by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $3.2M 188k 17.04

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Q32 Bio

OrbiMed Advisors
Atlas Venture Life Science Advisors
Carlyle
Vivo Capital
Arch Venture Corp
Temasek Holdings
5AM Venture Management
ADAR1 Capital Management
Platinum Investment Mangement
Vanguard Group
Exome Asset Management
BlackRock
Affinity Asset Advisors
Ensign Peak Advisors
BML Capital Management

View all funds holding Q32 Bio